GNFT News and Press, GENFIT S.A. From 01/22/24

2024-01-22 08:37:55 ET Rail Vision  ( RVSN ) +96% Successfully Secures Approval and Certifications and for EU Railway Standards. Nustar Energy ( NS ) +23% to buy NuStar in all-stock deal valued at $7.3B. MSP Recovery  ( LIFW ) +23% . North...

2023-12-08 08:20:25 ET MBIA  ( MBI ) +66% declares extraordinary cash dividend; shares up premarket Volato Group  ( SOAR ) +51% . FLJ Group  ( FLJ ) +23% . MicroAlgo ( MLGO ) +15% . Eneti  ( NETI ) +10% Announce Ext...

2023-11-27 10:34:03 ET More on Tharimmune, Inc. Financial information for Tharimmune, Inc. For further details see: Tharimmune stock rockets 46% on positive Phase 1 data for PBC drug

2023-11-27 07:30:00 ET Summary Genfit is close to possible approval for its drug team-up with Ipsen, with positive Phase 3 readouts having been achieved. The company focuses on developing therapeutic products for liver diseases, currently with a primary focus on Primary Biliary Ch...

2023-11-19 09:52:24 ET Summary Today, we revisit CymaBay Therapeutics, a clinical stage biopharma company focused on developing therapies for liver and chronic diseases. The company's primary product candidate, seladelpar, has shown positive results in treating primary biliary cho...

2023-11-13 20:41:53 ET More on Genfit Genfit GAAP EPS of -€0.42, revenue of €15.37M Seeking Alpha’s Quant Rating on Genfit Historical earnings data for Genfit Financial information for Genfit For further details see: Genfit st...

2023-11-13 18:01:34 ET Gainers: Theseus Pharmaceuticals ( THRX ) +35% . GENFIT  ( GNFT ) +15% . Lifeway Foods ( LWAY ) +9% . Digital World Acquisition ( DWACW ) +8% . Digital World Acquisition  ( DWAC ) +5% . Lose...

2023-09-20 16:21:53 ET More on Genfit Seeking Alpha’s Quant Rating on Genfit Historical earnings data for Genfit Financial information for Genfit Genfit gains as Phase 3 trial for liver disease candidate succeeds (update) For further details se...

2023-09-10 06:05:05 ET Summary Positive results achieved in phase 3 RESPONSE study, which used seladelpar for the treatment of patients with primary biliary cholangitis. Positive results of the phase 3 RESPONSE study leads to additional data at an upcoming medical meeting and poss...

2023-09-07 07:56:40 ET More on CymaBay Seeking Alpha’s Quant Rating on CymaBay Therapeutics Historical earnings data for CymaBay Therapeutics Financial information for CymaBay Therapeutics CymaBay Therapeutics, Inc. ( CBAY ) Q2 2023 Earnings Call...